Oddo BHF upgraded Pharma Mar to Outperform from Neutral with a EUR 48 price target. The company’s lung cancer drug Zepzelca has a lot of potential and the stock’s current low valuation creates a buying opportunity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly